rifapentine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, rifamycin derivatives | 2378 | 61379-65-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Rifapentine, a cyclopentyl rifamycin, inhibits DNA-dependent RNA polymerase in susceptible strains of Mycobacterium tuberculosis but does not affect mammalian cells at concentrations that are active against these bacteria. At therapeutic levels, rifapentine inhibits RNA transcription by preventing the initiation of RNA chain formation. It forms a stable complex with bacterial DNA-dependent RNA polymerase, leading to repression of RNA synthesis and cell death. Rifapentine and its 25-desacetyl metabolite accumulate in human monocyte-derived macrophages and are bactericidal to both intracellular and extracellular M. tuberculosis bacilli.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.11 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 70 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 22, 1998 | FDA | SANOFI AVENTIS US |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pyrexia | 39.18 | 37.98 | 25 | 268 | 470453 | 63018276 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pyrexia | 66.05 | 41.39 | 49 | 585 | 678660 | 79065094 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J04AB05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Antibiotics |
| FDA CS | M0019113 | Rifamycins |
| FDA EPC | N0000175501 | Rifamycin Antimycobacterial |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000904 | Antibiotics, Antitubercular |
| MeSH PA | D000995 | Antitubercular Agents |
| MeSH PA | D007917 | Leprostatic Agents |
| CHEBI has role | CHEBI:33231 | antitubercular agents |
| CHEBI has role | CHEBI:35816 | leprostatic drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pulmonary tuberculosis | indication | 154283005 | DOID:2957 |
| Alcoholism | contraindication | 7200002 | |
| Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
| Liver function tests abnormal | contraindication | 166603001 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pseudomembranous enterocolitis | contraindication | 397683000 | |
| Porphyria | contraindication | 418470004 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.06 | acidic |
| pKa2 | 7.26 | acidic |
| pKa3 | 11.03 | acidic |
| pKa4 | 11.77 | acidic |
| pKa5 | 12.55 | acidic |
| pKa6 | 7.87 | Basic |
| pKa7 | 2.32 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial DNA-directed RNA polymerase | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021127 | VUID |
| N0000148581 | NUI |
| D00879 | KEGG_DRUG |
| 4021127 | VANDF |
| C0073372 | UMLSCUI |
| CHEBI:45304 | CHEBI |
| RPT | PDB_CHEM_ID |
| CHEMBL1660 | ChEMBL_ID |
| DB01201 | DRUGBANK_ID |
| C018421 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12014 | IUPHAR_LIGAND_ID |
| 4765 | INN_ID |
| XJM390A33U | UNII |
| 135403821 | PUBCHEM_CID |
| 35617 | RXNORM |
| 7483 | MMSL |
| d04327 | MMSL |
| 007675 | NDDF |
| 108686006 | SNOMEDCT_US |
| 410831004 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Priftin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0088-2102 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 29 sections |
| Priftin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5063 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 29 sections |
| Priftin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5063 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 29 sections |
| Priftin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-1718 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 28 sections |